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ObituaryOn Sunday, March 15, 2009, Hidesaburo 
Hanafusa died in Osaka, Japan. He was 
79. With his passing, the scientific com-
munity lost a giant whose monumental 
achievements were matched only by his 
dignity, humility, honesty, and gener-
osity to collaborators and competitors 
alike. Scores of former trainees lost a 
beloved mentor, colleague, and friend, 
and his family lost a devoted husband, 
father, and grandfather. During a career 
that spanned six decades, two centu-
ries, three continents, and several cul-
tures, Hanafusa was a pioneer in virol-
ogy and molecular oncology. “Saburo” 
means third son, and the prefix “Hide” 
embellishes this with excellence and 
superiority. It was completely within 
character that he preferred to be known 
to students, friends, and colleagues sim-
ply as “Saburo.” However, excellence 
and superiority shine through his nearly 
300 publications notable for their origi-
nality and experimental precision; he 
made foundational contributions to our 
understanding of retroviral genetics, sig-
nal transduction, and oncogenesis. His 
work helped lay the groundwork for 
the so-called Oncogene Revolution 
that has begun to dramatically alter 
approaches to cancer therapy. His 
laboratory also produced several 
generations of investigators who 
have made important contributions 
to many fields. He will be sorely 
missed.
Saburo was born and educated 
in Japan. He had a hardscrabble 
upbringing because of the condi-
tions in Japan during and after World 
War II. Despite these hardships, 
intellectual pursuits were central 
to the family, and Saburo became 
the avatar of these aspirations. He 
received his PhD in biochemistry in 
1960 from Osaka University, where 
he also met his late first wife, Ter-
uko, the only woman in his class. In 
addition to their enduring marriage, 
the couple forged a powerful scien-
tific partnership, initially working on 
poxvirus replication.
By 1961, their interests had shifted 
to oncogenic retroviruses, and they left 
Osaka for Harry Rubin’s lab at UC Berke-
ley to work on Rous sarcoma virus (RSV), 
an RNA tumor virus that induces sarco-
mas in chickens. The startling discovery 
of a virus that causes cancer was made 
by Peyton Rous in 1911, but the mecha-
nism of RSV-mediated transformation 
remained an unsolved problem. Because 
we are living in a time when hundreds of 
human cancer genes have been defined, 
proteins can be sequenced in an after-
noon, and genomes sequenced in a 
week, it is perhaps difficult to appreciate 
how little was known about the molecular 
basis of cancer and how crude were the 
tools available to the Hanafusas when 
they arrived to work in Rubin’s lab.
Shortly before their arrival, Rubin and 
the late Howard Temin had made a major 
breakthrough with their focus-formation 
assay, in which “foci” of round trans-
formed cells would appear in flat mono-
layer cultures of chick embryo fibroblasts 
infected at limiting dilution. This assay 
allowed viral replication and transfor-
mation to be quantified. Peter Vogt and 
Rubin then found that when stocks of 
the Bryan high-titer strain of RSV were 
diluted, another virus could be isolated 
(termed Rous-associated virus; RAV). 
RAV did not form foci or sarcomas but 
could interfere with foci and tumor for-
mation induced by RSV. In experiments 
elegant in their simplicity, but supremely 
important for the future development of 
the field, Saburo and Teruko infected 
cells with highly dilute Bryan-RSV and 
overlaid the infected cultures with agar 
containing anti-RAV antibodies (Hana-
fusa et al., 1963). They then picked 
single foci of transformed cells and 
found that some foci did not produce 
infectious virus. Infectious transforming 
virus was subsequently recovered by 
super-infecting these transformed cells 
with RAV. The inescapable conclusion 
was that the Bryan-RSV was actually 
a mixture of one replication-defective 
virus capable of causing transformation 
and a helper virus (RAV) that provided a 
function essential for viral replication but 
not for transformation. The Hanafusas 
subsequently found this essential 
factor to be the RAV envelope gly-
coprotein (Hanafusa et al., 1964). 
These landmark studies established 
that transformation was genetically 
distinct from viral replication, laid 
the groundwork for future studies of 
the genetic content of retroviruses, 
and most importantly, strongly sug-
gested the existence of viral onco-
genes. The Hanafusas’ finding that 
defective retroviruses can transfer 
specific genetic information is the 
conceptual underpinning for the 
now ubiquitous use of retroviral and 
lentiviral vectors.
After a brief sabbatical in France, 
Saburo returned to the US in 1966 
in his first independent position, at 
the Public Health Research Institute 
of New York. Several major contri-
butions followed. First, in a remark-
able series of experiments aimed at 
deciphering the details of RSV rep-
lication in fibroblasts derived from 
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different chicken embryos, Teruko and 
Saburo discovered “chick helper factor,” 
providing early evidence for endogenous 
retroviruses (Hanafusa et al., 1970a, 
1970b).
Soon, however, the attention of the 
Hanafusas and other major retrovirology 
labs turned to the fundamental ques-
tion of elucidating the mechanism of cell 
transformation by RSV. The first step 
was to develop key reagents: two types 
of transformation-defective RSV mutants 
isolated by Saburo and the labs of Steve 
Martin, Vogt, and Peter Duesberg. Tem-
perature-sensitive RSV mutants could 
replicate without transforming cells at 
the nonpermissive temperature but trig-
gered transformation rapidly upon a shift 
to the permissive temperature. Restora-
tion of transformation was independent 
of new RNA synthesis but sensitive to 
protein synthesis inhibitors, implying the 
existence of a heat-labile transforming 
protein. The other type of transforma-
tion-defective RSV mutants (td mutants) 
contained deletions of various sizes in 
the viral genomic RNA. In collaboration 
with Lu-Hai Wang and Duesberg, Kawai 
and Hanafusa used RNAase T1 mapping 
to determine the location of the pro-
posed Src and Env genes on the retrovi-
ral genome (Wang et al., 1976). The stage 
was now set for momentous discoveries 
in molecular oncology. Dominique Ste-
helin, Harold Varmus, Michael Bishop, 
and Vogt prepared hybridization probes 
specific for the Src gene using td dele-
tion mutants to deplete viral sequences 
unrelated to transformation. Using these 
probes, they made the exciting discovery 
that normal cells contained Src-related 
sequences.
Saburo and colleagues, now at 
Rockefeller University, used an elegant 
“marker-rescue” experiment inspired by 
bacteriophage genetics (Hanafusa et al., 
1977) to search for a cellular Src gene. 
This experiment both recapitulated the 
likely evolution of RSV and demonstrated 
the transforming potential of the cellular 
Src gene. Saburo found that chickens 
injected with transformation-defective 
(deletion) mutants developed tumors, 
with long latency and distant from the 
site of injection (in contrast to the rapid 
and local tumorigenesis produced by 
transformation-competent RSV). Repli-
cation-competent transforming viruses 198 Cell 137, April 17, 2009 ©2009 Elsevier could be recovered from these tumors 
yet, intriguingly, produced foci that were 
morphologically distinct from the origi-
nal RSV (Hanafusa et al., 1977), suggest-
ing the generation of a new transform-
ing gene. Saburo concluded that these 
“recovered viruses” had, by recombi-
nation, captured the cellular Src gene. 
The conclusion was soon cemented by 
oligonucleotide fingerprinting, restriction 
mapping with heteroduplex analysis, 
peptide mapping, and, definitively, DNA 
sequencing of the cellular locus (Takeya 
and Hanafusa, 1983). For this landmark 
work, Saburo shared the 1982 Lasker 
Award for Biomedical Research.
The 1980s saw dizzying progress. The 
Hanafusa lab identified many new viral 
oncogenes (Yes, Fps, Ros) and their cog-
nate cellular genes. The laboratory also 
made important advances regarding the 
mechanism of transformation. RSV engi-
neered to carry c-Src instead of v-Src 
was found to be nontransforming; muta-
genesis and domain-swap experiments 
defined important regions for what is 
now known to be c-Src autoinhibition. 
Other studies defined a critical role for 
v-Src myristoylation and membrane tar-
geting for transformation, foreshadow-
ing the critical importance of membrane 
recruitment in receptor-tyrosine kinase 
signaling.
The close of the 1980s brought 
another breakthrough. Tony Pawson’s 
laboratory made the critical observa-
tion that, in addition to their conserved 
kinase (SH1) domains, Src and Fps 
shared other regions of sequence simi-
larity, which they termed “Src Homol-
ogy-2 (SH2)” and “Src Homology-3 
(SH3)” domains. However, the function 
of these domains was obscure. Bruce 
Mayer, then a graduate student in the 
Hanafusa lab, cloned and sequenced 
the transforming gene of CT10 (v-Crk). 
Surprisingly, it encoded a fusion of a viral 
Gag protein with an SH2 domain and an 
SH3 domain (Mayer et al., 1988). Thus, 
the SH2 and SH3 domains alone could 
be the business end of an oncoprotein. 
Subsequent studies from the group 
showed that v-Crk expression increased 
cellular phosphotyrosine levels, and that 
v-Crk bound to multiple phosphotyrosyl 
proteins, at least one of which was a 
tyrosine kinase. Furthermore, the SH2, 
and to a lesser extent the SH3, domains Inc.were required for transformation and the 
SH2 domain was necessary for binding 
to phosphotyrosine-containing proteins. 
Contemporaneous and subsequent 
studies from the Pawson lab and from 
Mayer (first with Hanafusa and later as a 
postdoctoral fellow with David Baltimore) 
showed directly that SH2 domains bind 
to phosphotyrosine-containing proteins. 
These studies established the paradigm 
that modular protein-protein interaction 
domains are building blocks of cellular 
signaling pathways. In 1993, for these 
and other contributions to the under-
standing of oncogenic signaling, Saburo 
received the Alfred P. Sloan Prize from 
the General Motors Cancer Research 
Foundation.
The discovery of SH2 and SH3 
domains also brought the long history of 
Rous sarcoma virus and the molecular 
basis of its transforming activity full cir-
cle. The recombination junction between 
c-Src and retroviral sequences replaced 
19 amino acids from c-Src, which most 
likely occurred in the initial recombination 
event that generated the virus isolated 
by Rous in 1911. Loss of this C-terminal 
sequence was itself sufficient for turn-
ing c-Src into an oncogene. Later bio-
chemical experiments and c-Src crys-
tal structures explained this: the c-Src 
C-terminal tail contained a tyrosine that, 
when phosphorylated, bound intramo-
lecularly to the SH2 domain, inactivating 
the c-Src kinase.
Saburo received many other honors, 
including the Order of Culture (the high-
est honor in Japan), the Howard Taylor 
Ricketts Award, the G.H. Clowes Memo-
rial award from the American Association 
for Cancer Research, and a Doctorate 
of Science, honoris causa, from Rock-
efeller. He also was a Foreign Associate 
of the US National Academy of Sciences 
and a member of the Japanese Academy 
of Sciences. He received the Japan Cul-
tural Merit Award and was an honorary 
member of the Japanese Societies for 
Virology and Cancer Research.
The scientific community will remem-
ber Hanafusa for his seminal work, but 
his students will surely remember him 
even more for his mentorship. He was a 
lover of ideas, with a profound apprecia-
tion of carefully executed and controlled 
experiments. Saburo was not a big 
talker; exciting and instructive conver-
sations happened, typically late at night 
and on weekends, but usually these con-
versations occurred while working side-
by-side at the bench. Often they were 
initiated by his laconic and somewhat 
playful query: “What it means?”
Given how quiet and reserved Saburo 
was, the degree of loyalty and affection 
he inspired is remarkable. Again deeds, 
not words, carried the day. He cared 
about his trainees and we knew it; he 
looked after the little things that mat-
tered to people. His house was often a 
jumbled way station for furniture being 
passed from one postdoc to the next. 
His laboratory was a melting pot for sci-
entists from all over the world. We came 
together, experienced each other’s cul-
tures, did exciting science, and formed 
lifelong friendships.
Although Saburo’s work ethic was 
legendary, he did have outside inter-
ests. He was dedicated to his daughter 
Kei, now a physician in San Francisco, 
as well as to his four grandchildren. He 
loved Beethoven, baseball, American 
football, Japanese sake, and a good 
whisky. He was an avid and highly com-
petitive softball player; rumor had it that 
he was a star baseball pitcher during his 
youth. By sheer force of personality he 
would corral all lab members, indepen-dent of cultural background or athletic 
prowess, to play softball at least once 
every summer. The results were fre-
quently comical, but he was too kind to 
laugh out loud.
After Teruko’s untimely death in 1996, 
Saburo returned to Japan in 1998 as 
Director of the Osaka Bioscience Insti-
tute. In Osaka, he had the good fortune 
to meet his second wife, Emiko. Though 
slowed by illness, he continued to con-
tribute to our understanding of oncogen-
esis while inspiring a new generation of 
Japanese scientists. He kept in touch 
with his former trainees and colleagues 
from the US, both remotely and at lab 
reunions held at the Osaka Bioscience 
Institute.
It is both ironic and cruel that Saburo, 
having contributed so much to our under-
standing of virology and oncogenesis, 
succumbed to liver cancer, a virus-asso-
ciated malignancy. Yet there is much to 
celebrate. He dedicated his career to a 
single biological problem and, as a result 
of his intense focus and dedication, had 
the satisfaction of playing a major role 
in solving it. He lived to see new cancer 
therapies developed directly from the 
Oncogene Revolution that he helped to 
create. He was a scientist’s scientist, 
publicity-shy, but, nevertheless, a widely Cellrecognized international figure. He was 
genuinely beloved by students, fellows, 
and colleagues. We all have to answer 
Saburo’s question of “what it means?” 
in our own way. But Hidesaburo Hana-
fusa answered it in a way that many of us 
could only hope to emulate.
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